Big data meets interactive virtual reality.
Being an advisor to several medical imaging publications, requires one to provide a prognosis of what the key dynamics in medical imaging might be in the following year.
At this point in time, I am personally involved in several areas: big data (BD) and interactive virtual reality (IVR). Both areas are beginning to take hold in terms of impacting patient outcomes (PO). This discussion is focused on the synergy between BD and IVR, and the resulting potential for significant gains in PO – an important dynamic for medical imaging.
The news about BD is increasing as IBM’s efforts with Watson are coming to fruition. It is most noteworthy that Virginia Rometty, IBM CEO, characterizes Watson as a cognitive-based system that represents supervised learning using BD techniques. Cognition is indeed a critical element in that it impacts knowledge, which is dependent on both cognition and intuition. Knowledge, in turn, represents a fundamental factor in driving PO.
The other critical element in the knowledge equation, intuition, has been shown to be driven by IVR. Hence, the power of the BD/IVR intersection.
Consider IVR as the ability to view an object in open 3D space and directly interact with the object (eg, removing a tumor electronically).
Radiologists have noted, that IVR provides a way to communicate more effectively with surgeons. Surgeons have noted that IVR allows them to finally achieve surgical visualization, the ability to view anatomy in a manner that corresponds to their 3D world view – they never open up patients and see 2D views.
Essentially, IVR represents a new paradigm, or “language,” with which different specialists discover an enhanced ability for communicating more effectively with one another.
Why might 2017 be the key year to realize the potential of the BD/IVR intersection? Based on several years of clinical trials, significant improvement in the core areas of PO, clinical efficacy (CE), and workflow (WF), have been demonstrated in a number of applications, due to IVR driven increases in knowledge.
We might think of IVR as focused on “doing the right things” and BD as focused on “doing things right.” A case in point would be a Protocol for optimizing both CE and WF for virtual colonoscopy. Based on the intuitive properties of IVR, a concept of dividing the colon into linear segments emerged with each segment separately analyzed for polyps. This breakthrough led to significant gains in both clinical efficacy and workflow.
BD has already been effectively applied to virtual colonoscopy. BD could also be applied to the analysis of all users of the above protocol to establish best practices from data representing all user motions (head, stylus, etc.). In this manner, BD is a key to “doing things right.” This direction was intimated by Shrestha.
The intersection of BD and IVR therefore provides a significant opportunity for achieving improvements in PO. We could think of this activity as knowledge modeling. Today, leading organizations in health care are establishing knowledge modeling as the core of effective data management. What could be better than to apply these principles to increasing PO?
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.